Dinutuximab
Aliases
Ch14.18, Ch 14.18UTC, Chimeric Monoclonal Antibody 14.18, Dinutuximab Beta, MAB Ch 14.18 (4 other aliases)
11 clinical trials
1 product
2 abstracts
9 indications
Indication
NeuroblastomaIndication
Metastatic OsteosarcomaIndication
OsteosarcomaIndication
Resectable NeuroblastomaIndication
Relapsed Solid TumorIndication
Solid TumorIndication
GanglioneuroblastomaIndication
NodularClinical trial
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2025-03-31
Abstract
Preliminary experience of ex-vivo expanded allogeneic universal donor TGFβi NK cell infusions in combination with irinotecan, temozolomide, and dinutuximab in patients with relapsed or refractory neuroblastoma: The Allo - STING trial.Org: Nationwide Children's Hosp, Columbus, OH, OHB Neonatology, Nationwide Childrens Hospital, Nationwide Children's Hospital,
Clinical trial
A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent OsteosarcomaStatus: Completed, Estimated PCD: 2020-03-31
Clinical trial
A Phase I Study of 131I-MIBG With Dinutuximab +/- Vorinostat for Relapsed/Refractory NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2023-06-15
Clinical trial
A Phase I/II Safety Lead in Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Irinotecan, Temozolomide, and Dinutuximab in Patients With Relapsed or Refractory Neuroblastoma: The Allo - STING TrialStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialStatus: Not yet recruiting, Estimated PCD: 2028-12-01
Clinical trial
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell RescueStatus: Active (not recruiting), Estimated PCD: 2012-01-12
Clinical trial
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)Status: Active (not recruiting), Estimated PCD: 2028-05-01
Clinical trial
A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- LenalidomideStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed OsteosarcomaStatus: Active (not recruiting), Estimated PCD: 2032-12-31
Clinical trial
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2018-09-14
Clinical trial
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Abstract
Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).Org: University Medicine Greifswald, Pediatric Hematology and Oncology, Pediatric Hematology and Oncology, Greifswald, Germany, Pediatric Hematology and Oncology,
Product
Unituxin + GM-CSF/IL-2 + RA